May 28, 2020 -- A supplier of active pharmaceutical ingredients (API), CordenPharma, has inked a manufacturing agreement with Moderna. CordenPharma will manufacture large-scale volumes of Moderna's lipid excipient which will be used to manufacture Moderna's SARS-CoV-2 vaccine candidate, mRNA-1273.
Under the agreement, the companies are expanding their supply relationship to include CordenPharma locations in France and the U.S. The initial relationship began in 2016 between Moderna and CordenPharma Switzerland. Now, CordenPharma will immediately provide specialized lipid manufacturing to help Moderna meet increased demand in the coming months.